Puente-Maestu, Luis http://orcid.org/0000-0001-8501-0117
Molina-París, Jesús
Trigueros, Juan A.
Gómez-Sáenz, J. Tomás
Cea-Calvo, Luis
Fernández, Sabela
Sánchez-Jareño, Marta
Domínguez-Ortega, Javier
Funding for this research was provided by:
MSD
Article History
Received: 7 May 2021
Accepted: 6 September 2021
First Online: 17 September 2021
Declarations
:
: Luis Puente-Maestu has received payment for consultancy services and presentations from MSD, AstraZeneca, Boston Scientific, Esteve, GSK, Chiesi, and Novartis. He has also been an adviser to AstraZeneca and has received institutional financial support from GSK, Esteve, Grifols, Zambon, Menarini, and Bial, as well as traveling and accommodation expenses for attendance at medical education meetings from Boston Scientific, Boehringer, Chiesi, and Novartis. Jesús Molina-París has received payment for acting as an adviser to GSK, acting as a consultant to AstraZeneca and GSK, and for preparing expert reports for GSK, AstraZeneca, Pfizer, and Novartis. Juan A. Trigueros has received research grants from GSK, AstraZeneca, Menarini, Teva, and Boehringer. J. Tomás Gómez-Sáenz has received payment for consultancy services and presentations from GSK, AstraZeneca, Reig Jofre, and Teva. Luis Cea-Calvo is a full-time employee of MSD, Spain. Sabela Fernández is a full-time employee of MSD, Spain. Marta Sánchez-Jareño is a full-time employee of MSD, Spain. Javier Domínguez-Ortega has received payment for consultancy services and presentations from Leti Pharma, Mundipharma, AstraZeneca, Chiesi, Novartis, GSK, MSD, Sanofi, and Teva.
: Not applicable.
: All the physicians consented to participate in the survey.
: All authors have reviewed and approved the final version of this manuscript and agree to the publication of the findings of the present study.